Shareholders of Petco Health and Wellness Company, Inc. Should Contact Levi & Korsinsky Before August 29, 2025 to Discuss Your Rights – WOOF

Shareholders of Petco Health and Wellness Company, Inc. Should Contact Levi & Korsinsky Before August 29, 2025 to Discuss Your Rights – WOOF GlobeNewswire July 31, 2025 NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Petco Health and Wellness Company, Inc. (“Petco” or the “Company”) (NASDAQ: WOOF) of […]

Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SRPT

Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SRPT GlobeNewswire July 31, 2025 NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) of a class action securities lawsuit. CLASS

Fortrea Holdings Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – FTRE

Fortrea Holdings Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – FTRE GlobeNewswire July 31, 2025 NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. (“Fortrea Holdings Inc.” or the “Company”) (NASDAQ: FTRE) of a class action securities

AppFolio, Inc. Announces Second Quarter 2025 Financial Results

AppFolio, Inc. Announces Second Quarter 2025 Financial Results Strong revenue growth driven by Realm-X adoption through premium tiers and value added services GlobeNewswire July 31, 2025 SANTA BARBARA, Calif., July 31, 2025 (GLOBE NEWSWIRE) — AppFolio, Inc. (NASDAQ: APPF) (“AppFolio” or the “Company”), a technology leader powering the future of the real estate industry, today

Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference

Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference GlobeNewswire July 31, 2025 REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference

AppFolio Names Tim Eaton as Chief Financial Officer

AppFolio Names Tim Eaton as Chief Financial Officer GlobeNewswire July 31, 2025 SANTA BARBARA, Calif., July 31, 2025 (GLOBE NEWSWIRE) — AppFolio (NASDAQ:APPF), the technology leader powering the future of the real estate industry, today announced that its Board of Directors has appointed Tim Eaton as the Chief Financial Officer of AppFolio, effective July 30,

Bimini Capital Management Announces Second Quarter 2025 Results

Bimini Capital Management Announces Second Quarter 2025 Results GlobeNewswire July 31, 2025 VERO BEACH, Fla., July 31, 2025 (GLOBE NEWSWIRE) — Bimini Capital Management, Inc. (OTCQB: BMNM), (“Bimini Capital,” “Bimini,” or the “Company”), today announced results of operations for the three-month period ended June 30, 2025. Second Quarter 2025 Highlights Net income of approximately $43

MATSON, INC. ANNOUNCES SECOND QUARTER 2025 RESULTS

— 2Q25 EPS of $2.92 versus $3.31 in 2Q24 — 2Q25 Net Income of $94.7million versus $113.2million in 2Q24 — 2Q25 Consolidated Operating income of $113.0million versus $124.6million in 2Q24 — 2Q25 EBITDA of $163.6million versus $171.5million in 2Q24 — Repurchased approximately 0.9million shares in 2Q25 — Raising full year outlook Matson, Inc. (“Matson” or

ICF Reports Second Quarter 2025 Results

Second Quarter in Line with Expectations Led by 27% Revenue Growth in Commercial Energy– Margins Continue to Benefit From Favorable Mix– Maintains Full Year 2025 Guidance Framework with Improved Business Outlook– Expects a Return to Revenue and Earnings Growth in 2026– Second Quarter Highlights: — Revenue Was $476 Million — Net Income Was $24 Million;

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

Conference call and webcast to be held at 4:30 p.m. ET Trevi Therapeutics, Inc.(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior

Scroll to Top